HIV and hepatitis C among injecting drug users

Success in preventing HIV has not been mirrored for hepatitis C

Injecting drug users have been capable of reducing their risky behaviour in the face of the HIV-AIDS epidemic.¹ To many this risk reduction, shown in numerous studies from different parts of the world, was unexpected as drug users are often regarded as self destructive. Nevertheless, because of the decrease in risky behaviour, the incidence of HIV infection among drug users in most industrialised countries has declined over the years. Thus, in this issue, van Beek et al report that among young injecting drug users in Sydney the incidence of HIV infection in 1992-5 was only 0.2 per 100 person years (p 433).² Not so good is their finding that the incidence of infection with hepatitis C virus (HCV) was extremely high: 21 per 100 person years; among those aged under 20 the rate was 76 per 100 person years. Other groups from different countries have also reported a continuing high prevalence and incidence of hepatitis C virus among injecting drug users,³ though not as high as in this study; this may be to do with the young age of the Australian group.

The low incidence (and prevalence) of HIV among injecting drug users in Australia may be ascribed to that country's public health approach, with wide implementation of preventive measures including needle and syringe exchange programmes. But how can we explain the discrepancy between the low incidence of HIV infection and the high incidence of hepatitis C? One reason is the difference in prevalence between the two viral infections. The prevalence of HIV in the Australian group was 2.5% while that of hepatitis C virus was 45%. So, if in that environment an injecting drug user shares injecting equipment with someone else the chance that this equipment is infected with hepatitis C virus is considerably greater than for HIV.

But this is not the only explanation. Hepatitis C virus is much more efficiently transmitted through blood than HIV infectionfor sexual transmission it is the other way around. The rate of hepatitis C virus antibody seroconversion among healthcare workers in Japan who had been exposed through needlestick injuries to blood from patients positive for hepatitis C virus was 3-9%.³ This is more than 10 times higher than the 0.3% HIV seroconversion rate after needlestick incidents with HIV positive patients.⁴ The high transmission efficiency of hepatitis C virus may also explain its transmission in drug users in the Australian study who did not report a history of sharing equipment. This could have been due to indirect sharingthat is, sharing of injecting accessories such as spoons and cottonor to front and back loadingdividing drugs by sticking the needle of one syringe into another (used) syringewhich is often not seen as sharing by drug users.

The clinical consequences of hepatitis C virus infection are serious, especially in the long term.⁵ Although most acute hepatitis C infections are subclinical, in 80-85% of cases the infection persists and usually leads to chronic hepatitis, which can result in cirrhosis and rarely hepatocellular carcinoma. The mean period between infection with the virus and its consequences is long: about 20 years for cirrhosis and 29 years for hepatocellular carcinoma. There is no convincing evidence that the progression to cirrhosis is influenced by drug use itself, but other risk factors like coinfection with hepatitis B and HIV and hepatotoxic agents like alcohol enhance progression. As these risk factors are common among injecting drug users, their incubation period between infection and its sequelae may be shorter. On the other hand, mortality among injecting drug users is high: a study among injecting drug users in the Netherlands showed 1.8 deaths per 100 person years in those who were HIV negative and 6.4 per 100 person years in those who were HIV positive.⁶ Therefore, some drug users with hepatitis C virus will not survive long enough to develop cirrhosis or carcinoma.

Because of its long term consequences hepatitis C virus infection should be treated, although the sustained response rate after treatment (currently with interferon, preferably in combination with ribavirin) is only 20-30%.⁷ Other drugs for treating the infection are being developed and may have better results.

What can we do about the hepatitis C virus epidemic in injecting drug users? It is clearly an extra reason to strengthen programmes aimed at reducing sharing of injecting equipment by drug users. However, many industrialised countries have, like Australia, already implemented such programmes and there seems to be only limited room for improvement. More attention could be paid to preventing indirect sharing, as this may be an important transmission route for hepatitis C virus. And peer educationwhich has been shown to be very effective among homosexual menis an option that has not been sufficiently explored among injecting drug users. But we have to remain realistic. The residual risk among injecting drug users will be hard to prevent, especially as part of this behaviour appears to be deliberate (unpublished data). In the Netherlands stopping injecting ("the switch") was recently the topic of a national campaign implemented by an organisation with close links to injecting drug users. Another approach is to try to prevent drug users from starting injecting. And, of course, the best option is not to use drugs at all.

We have been reasonably successful in stemming (but not stopping) the HIV epidemic among injection drug users. The Australian data show that we have not been at all successful in stemming the spread of hepatitis C virus.

R A Coutinho, Director and professor of epidemiology and control of infectious diseases. 

Division of Public Health and Environment, Municipal Health Service, 1018 WT Amsterdam, Netherlands

1. Van Ameijden EJC, Watters JK, van den Hoek JAR, Coutinho RA. Interventions among injection drug users: do they work?. AIDS 1995; 9(suppl A): S75-S84[Medline].

2. Van Beek I, Dwyer R, Dore GJ. Infection with HIV and hepatitis C virus among injecting drug users in a prevention setting: retrospective cohort study. BMJ 1998; 317: 433-437[Medline].

3. MacDonald M, Crofts N, Kaldor J. Transmission of hepatitis C virus: rates, routes and cofactors. Epidemiologic Reviews 1996; 18: 137-148[Medline].

4. Tokars JI, Marcus R, Culver DH, Schable CA, McKibben PS, Bandea CI, et al. Surveillance of HIV infection and zidovudine use among health care workers after occupational exposure to HIV-infected blood. Ann Intern Med 1993; 118: 913-919[Medline].

5. Van der Poel CL, Cuypers HT, Reesink HW. Hepatitis C virus six years on. Lancet 1994; 344: 1475-1479[Medline].

6. Van Haastrecht HJA, van Ameijden EJC, van den Hoek JAR, Mientjes GHC, Bax JS, Coutinho RA. Predictors of mortality in the Amsterdam Cohort of HIV-positive and HIV-negative drug users. Am J Epidemiol 1996; 143: 382-391.

7. Reichard O, Norkrans G, Frydén A, Braconier J-H, Sönnerborg A, Weiland O, for the Swedish Study Group. Randomised, double-blind, placebo-controlled trial of interferon -2b with and without ribavirin for chronic hepatitis C. Lancet 1998; 351: 83-87[Medline].